




EP/04/7617



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Andrew Gersey

Dated 6 July 2004

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

The
**Patent
Office**

01AUG03 EBZ6971-1/002806
P01/7700 0.00-0317999.1



The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet, from the Patent Office to help you fill in this form)

1.	Your reference	LB1826		
2.	Patent application number (The Patent Office will fill in this part)	0317999.1		
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	Université de Liege Quai van Beneden, 25 4020 Liege Belgium		
	Patents ADP number (if you know it)			
	If the applicant is a corporate body, give the country/state of its incorporation	Belgium 85 777 10001		
4.	Title of the invention	Improvements in or relating to drug delivery systems		
5.	Name of your agent (if you have one)	Barker Brettell		
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	10-12 Priests Bridge LONDON SW15 5JE		
	Patents ADP number (if you know it)	7442494003		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of Filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day/month/year)
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))			


Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document
Continuation sheets of this form

Description 11

Claim(s)

Abstract

Drawing(s) 4 + 4 

10. If you are also filing any of the following, state how many against each item.
Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination
(*Patents Form 9/77*)

Request for substantive examination
(*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature Barker Brettell Date

Barker Brettell

31 July 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Lance Butler

Tel: 020 8392 2234

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

IMPROVEMENTS IN OR RELATING TO DRUG DELIVERY SYSTEMS

FIELD OF THE INVENTION

- 5 This invention concerns improvements in or relating to drug delivery systems and has particular reference to genital drug delivery systems.

BACKGROUND TO THE INVENTION

- There is now accumulating evidence that epithelial cells may influence immune
10 reactions in squamous mucosa through the production of cytokines. Granulocyte Macrophage - Colony Stimulating Factor (GM-CSF) produced by keratinocytes acts as a selective chemoattractive molecule for the migration of dendritic cells (DC) into the epithelium and for their differentiation into Langerhans cells (LC) (Kaplan et al, 1992; Pastore et al, 1997). Exposure of LC/DC to GM-CSF *in*
15 *vitro* prolongs their survival and increases their capacity to present antigens to lymphocytes (Koch et al, 1990). Moreover, *in vivo*, a correlation has been observed between the amount of GM-CSF produced by some carcinomas and the distribution/differentiation of tumor-associated DC (Colasante et al, 1995). We have previously demonstrated, by using the organotypic raft culture system, that
20 GM-CSF is a potent factor for enhancing the colonization of LC/DC in a (pre)neoplastic epithelium formed *in vitro* (Hubert et al, 1999). Moreover, the infiltration of organotypic cultures by DC specifically induced the apoptosis of keratinocytes transformed by human papillomavirus (HPV) whereas DC were not affected (Hubert et al, 2001).

25

These data suggest that the recruitment of DC into a virus-infected and/or (pre)neoplastic epithelium might be beneficial not only by stimulating anti-viral and anti-tumor immune responses but also by inducing the death of virus-infected and transformed cells.

30

Morbidity and mortality caused by HPV infection is a major health problem in developing countries and in the industrialised world, where direct and indirect costs from disease are very high. HPVs are common sexually transmitted pathogens inducing a spectrum of diseases ranging from benign genital warts to invasive carcinoma. Some types of HPV have been shown to be directly involved in the malignant transformation process, especially in the uterine cervix. Up to 99 percent of cervical cancer and its precursors (squamous intraepithelial lesions; SIL) may be attributed to infection by oncogenic human papillomavirus (HPV)(Bosch et al, 1995). However, HPV alone is not sufficient for tumor progression (Herrington, 1995). The role of the intrinsic immunity in controlling HPV infection and the subsequent development of SIL is shown indirectly by the increased frequency of HPV-associated lesions in patients with depressed cell-mediated immunity (Petry et al, 1994; Ellerbrock et al, 2000). Although viral antigens are expressed in a majority of preneoplastic lesions, progression to invasive cancer may occur, suggesting the existence of some qualitative an/or quantitative perturbations in the antigenic presentation function . This hypothesis is reinforced by the observation that most genital warts and SILs are characterized by a decreased density and function of LC compared to the normal paired squamous epithelium (Giannini et al, 2002; McArdle and Muller, 1986; Morelli et al, 1994). Since the immune system clearly plays an important role in influencing the natural history of the disease, there is some evidence that immune response modifiers may have therapeutic value for these lesions. Because of the central role of DC/LC in the induction and regulation of cellular immune responses, pharmacological agents that modulate the recruitment and function of these cells might have clinical interest.

The current study was designed to evaluate the capacity of several pharmaceutical formulations to topically deliver GM-CSF on HPV-associated lesions.

One major problem associated with the genital drug delivery is that the physiological conditions imposed by the protective mechanisms of the cervix or the vagina often lead to a limited contact time of administered drugs with the mucosa and a short duration of therapeutic efficacy, making a frequent dosing regimen necessary. (Robinson and Bologna, 1994; Valenta et al, 2001). The patients are known to tolerate gels better than other conventional dosage forms such as inserts or ointments. Some bioadhesive polymers have attracted considerable attention for their opportunity to prolong the contact of drug with a mucosal surface, without inducing adverse local effects on the epithelium (Richardson et al, 1996).

SUMMARY OF THE INVENTION

In this study, we investigated the properties of hydroxypropylcellulose, polycarbophil, carbomer and poloxamer polymers. Cellulose derivatives have been widely used as thickening agents in cervico-vaginal formulations (Gauger, 1983; Lynas, 1980; MacKenzie et al, 1979). Carbopols and polycarbophils are acrylic acid polymers which have good bioadhesive properties and prolonged retention of the formulation at the site of administration (Knuth et al, 1993). Poloxamer, a block copolymer made of polyoxyethylene and polyoxypropylene, is also known for its excellent compatibility. It forms in situ a gelling liquid which has been recognized as a convenient dosage form of topical application. The liquid applied to topical area turns into gel with an increase in temperature. (Chang et al, 2002).

After incorporation of GM-CSF into these hydrogels, the different formulations were evaluated for their bioactivity after storage at 4 or 37°C and for their potential to recruit DC in organotypic cultures of HPV-transformed keratinocytes.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Proliferation response of TF-1 cell line after incubation with GM-CSF extracted at different time intervals from the hydrogels stored at 4°C or at 37°C.

5 Growth was measured by 3H-dTR incorporation. Each point shows the mean of 6 replicates and bars represent standard error.

Figure 2: Typical dendritic morphology of adherent human PBMC after culture with GM-CSF and IL-4 (May-Grünwald-Giemsa stain; magnification 200 x)

10

Figure 3: Phenotypical FACS analysis of adherent human PBMC after culture with GM-CSF and IL-4. Results are displayed as dot plots. All studies were performed with isotype controls and negativity limits were set according to their location.

15

Figure 4: Detection of DC pre-labelled with a fluorescent red probe in organotypic cultures of HPV-transformed keratinocytes (SiHa) in the absence (A) or in the presence of GM-CSF included (C) or not (B) into a polycarbophil gel at pH 6.9. Nuclei of keratinocytes are labelled in blue after DAPI staining.

20

DETAILED DESCRIPTION OF THE INVENTION

Analysis of the GM-CSF bioactivity following incorporation into different polymers at 4°C and 37°C using a bioassay with TF-1 cells

The GM-CSF biological activity after incorporation into the different hydrogels was measured at different intervals of time using a bioassay of growth stimulation with the GM-CSF-dependant TF-1 cell line. The injectable solution (Leucomax, Novartis, Brussels, Belgium) was chosen as positive control. The four polymers were tested at a pH value of 6.9 which was reported to be optimal for GM-CSF stability and which correspond to the pH value of the injectable solution (data from Novartis). As polycarbophil was found to be a particularly convenient

25

30

polymer for cervico-vaginal formulations and as it is usually recommended to develop cervico-vaginal formulations at acidic pH values, the polycarbophil hydrogel was also tested at pH 5.5.

- 5 As shown in Figure 1, there was a decrease in the bioactivity of the injectable solution of GM-CSF more important at 37°C than at 4°C which is in agreement with previous data (Pettit et al, 1997). We also observed an important reduction of GM-CSF activity after incorporation in the hydroxypropylcellulose (Klucel) or in the poloxamer hydrogel (Lutrol) at both temperatures. In contrast,
- 10 polycarbophil gel (Noveon) pH 5.5 seemed to induce a protection against GM-CSF degradation. However, this protective effect is not observed at pH 6.9. Carbomer (Carbopol) conserved an activity of GM-CSF similar to that observed with the injectable solution at both temperatures and during at least a week.
- 15 These results suggest that the polycarbophil (Noveon) at pH 5.5 could be convenient to topically apply GM-CSF on a squamous mucosa.

GM-CSF incorporated in the polycarbophil gel stimulates the recruitment of monocyte-derived DC in organotypic cultures of HPV-transformed keratinocytes in a similar manner as GM-CSF in solution

20

We investigated whether GM-CSF included in a polymer can modulate the ability of DC to infiltrate an *in vitro*-formed (pre)neoplastic epithelium, reminiscent of high-grade (pre)neoplastic lesions observed *in vivo*. Cells from the plastic

25 adherent fraction of human peripheral blood mononuclear cells cultivated in the presence of 800 U/ml of GM-CSF and 20 U/ml of IL-4 for 7 days showed a morphology of DC with abundant dendritic membrane protrusions (Figure 2). By FACS analysis, these cells also displayed typical phenotypical features of DC (Figure 3) with the presence of CD1a, CD4, CD86 and CD54 (ICAM-1)

30 antigens, a moderate expression of class II MHC (HLA-DR) molecules and the

absence of macrophage (CD14), B (CD20) and T (CD3) cell markers. DC were layered on top of organotypic cultures of HPV-transformed keratinocytes in the presence of GM-CSF incorporated or not in the polymer. The effect of GM-CSF on DC infiltration was assessed by examining cryosections of organotypic cultures frozen 48 hours after GM-CSF addition. The ability of the GM-CSF gel to modulate the infiltration of DC was determined by evaluating the number of fluorescent DC migrating into the organotypic cultures. Figure 4 illustrates representative experiments showing the density of fluorescein-labeled DC in HPV-transformed keratinocyte organotypic cultures incubated with or without exogenous GM-CSF incorporated or not in the polycarbophil gel. DC layered onto organotypic cultures of SiHa poorly infiltrated the epithelial cell layers in the absence of GM-CSF (Fig 4A), whereas GM-CSF in solution or incorporated in the gel caused a significant increase in the density of DC observed within the epithelial sheet (Fig 4B-C).

Different mucoadhesive drug delivery systems based on hydrogels have been recently developed (Eouani et al, 2001; Peppas and Sahlin, 1996; Shawesh et al, 2002). Their ability to interact with mucus glycoproteins and to remain localized to a specific site might help to deliver molecules important for the anti-viral or anti-tumor immune responses. We have previously shown that GM-CSF increases the ability of monocyte-derived dendritic cells (DC) to infiltrate a (pre)neoplastic epithelium formed *in vitro*, suggesting that the effect of a treatment based on the local administration of GM-CSF might be a recruitment into the dysplastic epithelium of Langerhans cells (LC) (Hubert et al, 1999). LC are the main professional antigen-presenting cells in squamous mucosa. These cells are able to capture viral or tumor antigens and, after migration in the draining lymph nodes, to present these antigens to T cells. Subsequently, the sensitized T lymphocytes could reach the squamous epithelium and kill the cells bearing the antigens at the origin of the sensitization.

In this study, we analyzed the stability and bioactivity of GM-CSF in different formulations of hydrogels. As the quantitative and functional deficit of Langerhans cells is a constant immune alteration in genital HPV-associated lesions (Viac et al, 1993), we used the organotypic culture system of HPV-
5 transformed keratinocytes (Delvenne et al, 1995; Jacobs et al, 1998; Hubert et al, 1999; Delvenne et al, 2001, Renard et al, 2002).

We first demonstrated that polycarbophil gel at pH 5.5 conserves the bioactivity of GM-CSF at 4 or 37°C for at least 7 days, whereas a decrease in the biological activity of GM-CSF was observed mainly after incorporation in the
10 hydroxypropylcellulose or in the poloxamer hydrogels at both temperatures. This could be due to interactions with the polymers which are present in the formulations at a high concentration in order to achieve the suitable viscosity.

The residual bioactivity of GM-CSF incorporated into both gels at pH 6.9 was
15 surprisingly different. These data could be attributed to the carboxyl group present in the polycarbophil gel and absent in the hydroxypropylcellulose and poloxamer formulations. Indeed, similar results were reported with carboxylic acid containing polymers and carbomers which were shown to inhibit the degradation of insulin and other peptide drugs (Bai et al, 1996). The GM-CSF
20 bioactivity evaluated after storage in the polycarbophil hydrogel formulated at a pH value of 5.5 was better than that observed for GM-CSF in solution. Moreover, the fact that the pH value must be decreased in order to observe the protective effect of the polymer is completely compatible with the physiological cervico-vaginal pH.

25

Since the bioassay with TF-1 cells required the extraction of the GM-CSF from the different hydrogels, the bioactivity detected was that of solutions of GM-CSF. It was, therefore, important to determine whether the gel affected or not the activity of GM-CSF. Indeed, due to their viscosity, the hydrogels could
30 interfere with the diffusion and the biodisponibility of the GM-CSF. We have

demonstrated that GM-CSF included in the polycarbophil gel at pH 5.5 stimulated the infiltration of DC into an in vitro equivalent of HPV-associated (pre)neoplastic epithelium, suggesting that this hydrogel does not impair the protein release in vitro.

5

All together, these results suggest that the polycarbophil gel (Noveon) is compatible with the diffusion of bioactive GM-CSF with the advantage to stabilize the protein. Moreover, GM-CSF included in this platform is also able to recruit DC into HPV-transformed (pre)neoplastic epithelial sheets. This
10 formulation which is recommended for genital application might restore some immune functions which have been shown to be altered in HPV-associated lesions.

15 **Examples of Materials and Methods used in accordance with the invention.**

Preparation of the hydrogels

Poloxamer P407 (Lutrol) was supplied from BASF, Germany. Carbomer (Carbopol 974P) and Polycarbophil (Noveon AA1) were a gift from Noveon,
20 Belgium. Hydroxypropyl cellulose (Klucel GF) was obtained from Herkules. GM-CSF was received from Novartis (Brussels, Belgium). All other chemicals were of analytical grade.

25

- Preparation of carbopol gel :

The gel (1.3% w/w) was prepared by dispersing the carbopol resin in purified water. The mixture was stirred until thickening occurred and then neutralized by

dropwise addition of 40% (w/w) tromethamol, until a transparent gel appeared. Quantity of tromethamol was adjusted to achieve gel pH 6.9.

- *Preparation of polycarbophil gel*

- 5 The gel (1.0% w/w) was prepared by dispersing the Noveon AA1 in purified water. The mixture was stirred until thickening occurred and then neutralized by dropwise addition of 40% (w/w) tromethamol, until a transparent gel appeared. Quantity of tromethamol was adjusted to achieve gel pH 6.9 or 5.5

10 - *Preparation of poloxamer gel:*

The poloxamer gel was prepared by using the cold method. Poloxamer P407 20%(w/w) was slowly added under gentle mixing to a pH 6.9 phosphate buffer 0.05M at a temperature of 4°C . The mixture was allowed to dissolve overnight at 4°C until a clear solution was obtained.

15

- *Preparation of the hydroxypropylcellulose gels :*

Hydroxypropylcellulose 7 %(w/w) was slowly added to a pH 6.9 phosphate buffer 0.05M under gentle mixing until a transparent gel appeared

20 *Incorporation and extraction of GM-CSF into the different polymers*

900 pg of GM-CSF, diluted in RPMI with 2% FCS, were incorporated per gram of different gels by gently mixing. The gels were kept for different periods of time at obscurity and at 37°C or 4°C. After 0, 24, 48, 72 and 163 hours, the gels were diluted with 6 ml of RPMI 2% FCS in order to extract the GM-CSF.

- 25 After a filtration on 0.45 µm pore filters (Millex-HV, Millipore, Bedford, MA), solutions were stored at -20°C before the bioassay. GM-CSF in solution was also kept during the different intervals of time at 37°C and 4°C and filtered before storage.

Bioassay using TF-1 cell line

The factor-dependent human cell line TF-1 (ATCC, CRL-2003) was cultivated following previously published recommendations (Kitamura et al, 1989) with
5 minor modifications. Briefly, the cells were incubated in RPMI 1640 medium containing 10% fetal bovine serum and 5 ng/ml GM-CSF at 37°C 5% CO₂. Cells were deprived of GM-CSF for 24 hours and were cultured in the presence of 2% FCS. The cells were plated in a round-bottom 96 well microtiterplate at 50,000 cells per well, in 100 µl RPMI 2% FCS and 100 µl of GM-CSF included in the
10 different polymers for various intervals of time. The tests were performed in quintuplicate. The cultures were incubated for 24 hours in the presence of ³H-TdR (2 µCi/well, 7 Ci/mmol, Moravsek Biochemicals, CA). Cells were harvested by an automated sample harvester (Packard, Canberra, Tilburg, The Netherlands) and counted in a liquid scintillation counter (Top Count, Packard, Canberra).

15

Dendritic cell cultures and labeling with lipophilic fluorescent cell tracer.

DC were generated from the adherent fraction of human PBMC with 800 U/ml GM-CSF (Novartis, Brussels) and 20 U/ml IL-4 (Biosource Europe, Nivelles,
20 Belgium), as previously described (Hubert et al, 1998). DC generated for this study constituted a 90% pure cell population based on several criteria including morphology, forward-scatter and side-scatter values observed by FACS analysis and surface phenotype (CD1a⁺, CD14⁻, CD4⁺, CD54⁺, ...).

25 The DC were labeled with a lipophilic fluorescent marker (CM-DiL, Molecular Probes, Leiden, The Netherlands) according to a previously described procedure with minor modifications. Briefly, 4 x 10⁶ DC were resuspended in 1 ml of PBS and heated to 37°C. CM-DiL was diluted in 1 ml of PBS preheated to 37°C to obtain a final concentration of 16 µg/ml. The dye was mixed for several seconds
30 until the dye was evenly distributed. This solution was immediately transferred to

the cell suspension and rapidly mixed by pipetting. The cells were incubated for 2 min at 37°C, then for 2 min on ice. Finally, they were transferred in 40 ml of PBS at 4°C, centrifuged and resuspended in the appropriate medium.

5 *Organotypic cultures*

Organotypic cultures of HPV-transformed keratinocytes (SiHa cell line, Friedl et al. 1970) were prepared as previously reported (Hubert et al, 1999). After a 2 week stratification of keratinocytes, labeled DC were seeded on top of the *in vitro* formed epithelium at a concentration of 2×10^5 cells/50 μ l of growth medium. The organotypic culture was then placed on the different gels containing or not 8000U/ml of GM-CSF. The positive control was a solution of liquid GM-CSF at 8000U/ml. After 48 h at 37°C, the collagen rafts were harvested. The cultures were then embedded in O.C.T. compound (Tissue Tek, Sakura, Netherlands) at - 70°C and sectioned with a cryostat. The organotypic cultures were counterstained with the fluorescent dye 4', 6-Diamidine-2-phenylindole Dihydrochloride (DAPI, Roche Diagnostics, Brussels, Belgium). Infiltration of fluorescent DC was visualized with a fluorescent microscope (Leica DMLB microscope, Heidelberg GmbH, Germany) equipped with a 40x objective.

Figure 1




Figure 2




Figure 3






Figure 4

A



B



C



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.